Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096843 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
A Phase 2 study of Primary Membranous Nephropathy, sponsored by Climb Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT07096843: Recruiting Phase 2 study of Primary Membranous Nephropathy, sponsored by Climb Bio.
NCT07096843 is a Phase 2 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Climb Bio. The registered enrollment target is 45 participants, below the 131-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07096843, a Phase 2 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Climb Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Primary Outcome
Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.
Conditions Studied
Interventions
- DRUG budoprutug
Study Locations (20)
Other
- Climb Bio Investigative Site# 602 - Buenos Aires
- Climb Bio Investigative Site# 603 - Buenos Aires
- Climb Bio Investigative Site #601 - CABA
- Climb Bio Investigative Site #604 - CABA
- Climb Bio Investigative Site #605 - Córdoba
- Climb Bio Investigative Site #606 - Santa Fe
- Climb Bio Investigative Site #502 - Belo Horizonte
- Climb Bio Investigative Site #505 - Minas Gerais
- Climb Bio Investigative Site #506 - Pernambuco
- Climb Bio Investigative Site #501 - Porto Alegre
- Climb Bio Investigative Site #503 - São Paulo
- Climb Bio Investigative Site #504 - São Paulo
Texas
- Climb Bio Investigative Site #103 - El Paso
- Climb Bio Investigative Site #104 - Sherman
Colorado
- Climb Bio Investigative Site #110 - Denver
Florida
- Climb Bio Investigative Site #105 - Orlando
Georgia
- Climb Bio Investigative Site #108 - Atlanta
Indiana
- Climb Bio Investigative Site #106 - Indianapolis
New York
- Climb Bio Investigative Site #101 - Clifton Park
Pennsylvania
- Climb Bio Investigative Site #102 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT07096843 shows while recruiting
NCT07096843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 131-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which budoprutug is the first listed.
NCT07096843 names 20 study sites across 8 states, led by Other, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT07096843 about?
NCT07096843 is a clinical study titled "A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy". To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
What is the current status of trial NCT07096843?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-08-25. Estimated completion is 2027-10.
What conditions does trial NCT07096843 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT07096843?
The interventions under investigation include: budoprutug (DRUG).
Who is sponsoring clinical trial NCT07096843?
This trial is sponsored by Climb Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096843 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07096843's enrollment target sits among peer trials
45 8th of 8 higher than 1 of 8 other Primary Membranous Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Membranous Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RECRUITING · Phase 2
-
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI